Clinical trial
A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus…
NCT01089517 · Ophthotech Corporation, Industry · Completed
Key facts
| NCT number | NCT01089517 |
|---|---|
| Title | A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration |
| Official title | A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular Degeneration |
| Lead sponsor | Ophthotech Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Age-Related Macular Degeneration |
| Intervention type | Drug |
| Interventions | E10030 plus Lucentis, Lucentis |
| Enrollment | 449 |
| Start date | Mar 1, 2010 |
| Primary completion | Jun 1, 2012 |
| Completion | Jun 1, 2012 |
| First posted | Mar 18, 2010 |
| Last update posted | Mar 19, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: